Skip to search formSkip to main contentSkip to account menu

galiximab

Known as: anti-CD80 Antibody, anti-B7-1, anti-CD80 
A chimeric IgG1 monoclonal antibody directed against CD80, the natural ligand for the T-cell antigen CD28 which mediates T-cell and B-cell adhesion… 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

IDEC-114

Broader (1)

Monoclonal Antibodies
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Galiximab (anti-CD80)-induced growth inhibition and prolongation of survival in vivo of B-NHL tumor xenografts and potentiation by the combination with fludarabine
Galiximab is a primatized monoclonal antibody that targets CD80 expressed on malignant B cells and is being studied in the clinic… 
Review
2010
Review
2010
Galiximab: a review
Importance of the field: A significant number of patients relapse or do not respond to rituximab due to intrinsic or acquired… 
2010
2010
Galiximab in relapsed hodgkin lymphoma.
SS In general, patients with relapsed Hodgkin lymphoma are divided between those who can undergo an autologous stem cell… 
2009
2009
Anti-CD80 monoclonal antibody: galiximab
In recent years, the major approach to cancer therapy is rapidly moving away from the standard use of myelosuppressive… 
Review
2008
Review
2008
The use of galiximab in non-Hodgkin lymphoma.
Monoclonal antibodies are expanding the therapeutic options for patients with B-cell lymphoma. Despite the antitumor activity of… 
2008
2008
Durable Responses in Patients Treated with Galiximab (Anti-CD80) in Combination with Rituximab for Relapsed or Refractory Follicular Lymphoma: Long-Term Follow-up of a Phase II Clinical Trial.
Galiximab is an anti-CD80 monoclonal antibody with human IgG1 constant regions and macaque variable regions. CD80 is an immune… 
2008
2008
FLIPI Score Is Applicable and Predictive of Response to Upfront Immunotherapy in CALGB 50402: Phase II Trial of Extended Induction Galiximab ([G] anti-CD80 monoclonal antibody) Plus Rituximab [R].
The majority of indolent B-cell lymphoma patients [pts] receive R, either as a single agent or in combination with chemotherapy… 
2005
2005
Updated Results from a Phase II Study of Galiximab (Anti-CD80) in Combination with Rituximab for Relapsed or Refractory, Follicular NHL.
Galiximab is a PRIMATIZED®, anti-CD80, monoclonal antibody with human IgG1 constant regions and macaque variable regions. CD80 is… 
2003
2003
Gateways to clinical trials. March 2003.
Gateways to clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
1997
1997
Distinct roles for B7-1 and B7-2 determinants during priming of effector CD8+ Tc1 and regulatory CD4+ Th2 cells for contact hypersensitivity.
Contact hypersensitivity (CHS) is a CD8+ T cell-mediated response to hapten sensitization and challenge of the epidermis. Both… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)